header logo image


Page 1,206«..1020..1,2051,2061,2071,208..1,2201,230..»

New single-cell analysis reveals complex variations in stem cells

December 5th, 2014 9:40 pm

Stem cells offer great potential in biomedical engineering due to their pluripotency, which is the ability to multiply indefinitely and also to differentiate and develop into any kind of the hundreds of different cells and bodily tissues. But the precise complexity of how stem cell development is regulated throughout states of cellular change has been difficult to pinpoint until now.

By using powerful new single-cell genetic profiling techniques, scientists at the Wyss Institute for Biologically Inspired Engineering and Boston Children's Hospital have uncovered far more variation in pluripotent stem cells than was previously appreciated. The findings, reported today in Nature, bring researchers closer to a day when many different kinds of stem cells could be leveraged for disease therapy and regenerative treatments.

"Stem cell colonies contain much variability between individual cells. This has been considered somewhat problematic for developing predictive approaches in stem cell engineering," said the study's co-senior author James Collins, Ph.D., who is a Wyss Institute Core Faculty member, the Henri Termeer Professor of Medical Engineering & Science at MIT, and a Professor of Biological Engineering at MIT. "Now, we have discovered that what was previously considered problematic variability could actually be beneficial to our ability to precisely control stem cells."

The research team has learned that there are many small fluctuations in the state of a stem cell's pluripotency that can influence which developmental path it will follow.

It's a very fundamental study but it highlights the wide range of states of pluripotency," said George Daley, study co-senior author, Director of Stem Cell Transplantation at Boston Children's Hospital and a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. "We've captured a detailed molecular profile of the different states of stem cells."

Taking this into account, researchers are now better equipped to manipulate and precisely control which cell and tissue types will develop from an individual pluripotent stem cell or stem cell colony.

"The study was made possible through the use of novel technologies for studying individual cells, which were developed in part by collaborating groups at the Broad Institute, giving our team an unprecedented view of stem cell heterogeneity at the individual cell level," said Patrick Cahan, co-lead author on the study and Postdoctoral Fellow at Boston Children's Hospital and Harvard Medical School.

Researchers explored the developmental landscape of pluripotent stem cells by perturbing them with variants such as different chemicals, culture environments, and genetic knockouts. Then, they analyzed the individual genetic makeup of each cell to observe micro-fluctuations in each stem cell's state of pluripotency. They discovered many small nuances in the way stem cells are influenced by internal, chemical and environmental cues, revealing a complex "decision making" circuit of developmental regulators.

"These emerging single-cell analytics allow us to classify cells very precisely and identify regulatory circuits that control cell states," said the study's co-lead author Roshan Kumar, a former Wyss Institute Postdoctoral Fellow who is now a Senior Scientist at HiFiBiO Inc. and a Visiting Scholar at the Wyss Institute. "The real motivating force behind this study was to understand the causes and consequences of differences between individual stem cells and how the balance of key regulators within a cell can affect that cell's developmental outcome."

Looking at the findings, the researchers now believe there is a "code" that relates patterns of dynamic behavior in stem cell regulatory circuits to the developmental path a cell ends up taking. By leveraging that code, they hope to dial in precisely to specific individual cell states and to use them for a variety of purposes, such as creating certain cell types that a patient's body may be unable to produce on its own.

Read the original post:
New single-cell analysis reveals complex variations in stem cells

Read More...

Professor Eva Sykova about experiments using stem cell in Institute of Experimantal Medicine – Video

December 5th, 2014 7:43 pm


Professor Eva Sykova about experiments using stem cell in Institute of Experimantal Medicine
In the Institute of Experimantal Medicine in Czech Republic scientists work on a lot of diseases, brain injury, spinal cord injury, Alzheimer #39;s disease, Parkinson #39;s disease, amyotrophic lathero...

By: Bio-Tech Media

Continue reading here:
Professor Eva Sykova about experiments using stem cell in Institute of Experimantal Medicine - Video

Read More...

Stem cells applications in CNS disorders – Professor Eva Sykova – Video

December 5th, 2014 7:43 pm


Stem cells applications in CNS disorders - Professor Eva Sykova
In central nervous system there are many diseases that are incurable. So far, scientists learned how to treat only the symptoms of those diseases, so stem cells are the only candidates to treat...

By: Bio-Tech Media

Follow this link:
Stem cells applications in CNS disorders - Professor Eva Sykova - Video

Read More...

Fully functioning, miniature human stomach using pluripotent stem cells – Video

December 4th, 2014 3:49 pm


Fully functioning, miniature human stomach using pluripotent stem cells
Fully functioning, miniature human stomach using pluripotent stem cells. Subscribe this channel to watch more motivational, inspirational, valuable and infor...

By: Health Mind Body Spirit

Read more from the original source:
Fully functioning, miniature human stomach using pluripotent stem cells - Video

Read More...

Study identified a possible source of stem cells, can advance regenerative and fertility research – Video

December 4th, 2014 3:49 pm


Study identified a possible source of stem cells, can advance regenerative and fertility research
Study identified a possible source of stem cells, can advance regenerative and fertility research. Subscribe this channel to watch more motivational, inspira...

By: Health Mind Body Spirit

See the original post here:
Study identified a possible source of stem cells, can advance regenerative and fertility research - Video

Read More...

Actual Surgical Footage of the BMAC for Knee Osteoarthritis Procedure – Mayo Clinic (GRAPHIC video) – Video

December 4th, 2014 3:49 pm


Actual Surgical Footage of the BMAC for Knee Osteoarthritis Procedure - Mayo Clinic (GRAPHIC video)
Shane Shapiro, M.D., orthopedic physician at Mayo Clinic in Florida, performS a bone marrow aspiration and concentration for BMAC/stem cell injection into arthritic knees. This procedure is...

By: Mayo Clinic

Read the original post:
Actual Surgical Footage of the BMAC for Knee Osteoarthritis Procedure - Mayo Clinic (GRAPHIC video) - Video

Read More...

Bone Marrow Stem Cell Treatment (BMAC) for Knee Osteoarthritis – Mayo Clinic – Video

December 4th, 2014 3:49 pm


Bone Marrow Stem Cell Treatment (BMAC) for Knee Osteoarthritis - Mayo Clinic
Shane Shapiro, M.D., orthopedic physician at Mayo Clinic in Florida, discusses a regenerative medicine clinical research trial to treat knee arthritis, which is the bone marrow stem cell treatment...

By: Mayo Clinic

View post:
Bone Marrow Stem Cell Treatment (BMAC) for Knee Osteoarthritis - Mayo Clinic - Video

Read More...

Laminine – Seminar Diabetes – Video

December 4th, 2014 3:47 pm


Laminine - Seminar Diabetes
Apa manfaat Laminine bagi penderita diabetes? Kunjungi website kami facebook: http://www.facebook.com/superlaminine website : http://lamininestemcell.com Contacts: LIA MASTURA Phone: ...

By: Laminine Nutrisi Stem Cell Terbaik

Continue reading here:
Laminine - Seminar Diabetes - Video

Read More...

Cytori Expects New Japan Laws to Boost Adoption of Cytori Cell Therapy

December 4th, 2014 9:42 am

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) today confirmed that two Japanese regenerative medicine laws, which went into effect on November 25, 2014, remove regulatory uncertainties and provide a clear path for the Company to commercialize and market Cytori Cell Therapy and its Celution System under the Companys existing and planned regulatory approvals.

Japans new regenerative medicine laws substantially clarify regulatory ambiguities of pre-existing guidelines and this news represents a significant event for Cytori, said Dr. Marc Hedrick, President & CEO of Cytori. We have a decade of operating experience in Japan and Cytori is nicely positioned to see an impact both on existing commercial efforts and on our longer-term efforts to obtain therapeutic claims and reimbursement for our products.

Under the two new laws, Cytori believes its Celution System and autologous adipose-derived regenerative cells (ADRCs) can be provided by physicians under current Class I device regulations and used under the lowest risk category (Tier 3) for many procedures with only the approval by accredited regenerative medicine committees and local agencies of the Ministry of Health, Labour and Welfare (MHLW). This regulatory framework is expected to streamline the approval and regulatory process and increase clinical use of Cytori Cell Therapy and the Celution System over the former regulations.

Before these new laws were enacted, the regulatory pathway for clinical use of regenerative cell therapy was one-size-fits-all, irrespective of the risk posed by certain cell types and approaches, said Dr. Hedrick. Now, Cytoris point-of-care Celution System can be transparently integrated into clinical use by providers under our Class I device status and the streamlined approval process granted to cell therapies that pose the lowest risk. Our technology is unique in that respect.

Cytoris Celution System Is in Lowest of Three Risk Categories

The Act on the Safety of Regenerative Medicines and an amendment of the 2013 Pharmaceutical Affairs Act (the PMD Act), collectively termed the Regenerative Medicine Laws, replace the Human Stem Cell Guidelines. Under the new laws, the cell types used in cell therapy and regenerative medicine are classified based on risk. Cell therapies using cells derived from embryonic, induced pluripotent, cultured, genetically altered, animal and allogeneic cells are considered higher risk (Tiers 1 and 2) and will undergo an approval pathway with greater and more stringent oversight due to the presumed higher risk to patients. Cytoris Celution System, which uses the patients own cells at the point-of-care, will be considered in the lowest risk category (Tier 3) for most cases, and will be considered in Tier 2 if used as a non-homologous therapy.

Streamlined Regulatory Approval for Certain Medical Devices

In the near future, Cytori intends to pursue disease-specific or therapeutic claims and reimbursement for Cytoris Celution System and the Company would, at that point, sponsor a clinical trial to obtain Class III device-based approval and reimbursement. The new laws include changes to streamline regulation of Class II and some Class III devices, which will now require the approval of certification bodies rather than the PMDA, similar to the European notified body model. To date, certification bodies have only been used for some Class II devices.

Conditional Regulatory Approval and Reimbursement Potential

As a supplementary benefit to Cytori, the Company may also choose to take advantage of the new conditional approval opportunities granted under the new laws. Once clinical safety and an indication of efficacy are shown, sponsors may apply for their cell product to receive conditional approval for up to seven years and may be eligible for reimbursement under Japans national insurance coverage. Under the conditional approval, the sponsor can then generate post-marketing data to demonstrate further efficacy and cost effectiveness.

See more here:
Cytori Expects New Japan Laws to Boost Adoption of Cytori Cell Therapy

Read More...

10 Regenerative Medicine and Applications of Stem Cell Research June 1, 2010) – Video

December 3rd, 2014 5:44 pm


10 Regenerative Medicine and Applications of Stem Cell Research June 1, 2010)

By: tawkaw OpenCourseWare

Read the rest here:
10 Regenerative Medicine and Applications of Stem Cell Research June 1, 2010) - Video

Read More...

The application of stem cells in AD – Prof Eva Sykova – Video

December 3rd, 2014 12:42 am


The application of stem cells in AD - Prof Eva Sykova
Neurobiologist do not have good markers for Alzheimer #39;s diseese which able early diagnosis. Thus, usually the AD patients have fully developed pathology in brain. Using stem cells scientists...

By: Bio-Tech Media

See the original post here:
The application of stem cells in AD - Prof Eva Sykova - Video

Read More...

Global Stem Cell Groups Stem Cell Training to Launch Post-graduate Studies Program in Stem Cell Therapies and …

December 2nd, 2014 6:41 am

MIAMI (PRWEB) December 01, 2014

MIAMI, Dec. 1, 2014Stem Cell Training, Inc., a division of Global Stem Cells Group, Inc., has announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2015.

The program will include five days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Global Stem Cells Group Advisory Board member Dr. David B. Harrell, PhD will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.

Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and FDA registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting

The graduate course is to be held four times in Miami in 2015.

Course details, objectives and instruction include:

Didactic Lectures will include:

For additional information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Read the original here:
Global Stem Cell Groups Stem Cell Training to Launch Post-graduate Studies Program in Stem Cell Therapies and ...

Read More...

Kidney organ regeneration research leaps forward

December 2nd, 2014 6:41 am

Okayama City, Japan (PRWEB UK) 2 December 2014

Researchers at Okayama University Graduate School of Medicine and Kyorin University School of Medicine have successfully generated a kidney-like structure from just a single cell.

It has been predicted that the kidney will be among the last organs successfully regenerated in vitro due to its complex structure and multiple functions, states Shinji Kitamura, Hiroyuki Sakurai and Hirofumi Makino at the beginning of their latest report, before continuing to describe results suggesting a far more positive prognosis for the pace of kidney regeneration research. Despite the anatomical challenges posed by the kidney anatomy and the complexities understood from embryonic kidney development processes, the researchers have demonstrated that kidney-like structures can be generated from just a single adult kidney stem cell.

In embryos, kidney development requires two types of primordial cells cells at the earliest stage of development. However by generating kidney-like structures from a single type of kidney stem cell the researchers provide evidence for differences in the organ development in adults and embryos.

Kitamura, Sakurai and Makino researchers from Okayama and Kyorin Universities - took kidney stem cells from the different kidney components of microdissected adult rats and grew them in culture. A method for growing three-dimensional cell clusters showed that kidney-like structures could form so long as the initial cell cluster was large enough.

The minimum cluster size required might suggest that not all the kidney stem cells have stem cell characteristics. Therefore the researchers cloned kidney stem cells and confirmed that kidney-like structures still formed from the clusters of clone cells after a few weeks.

The researchers add, Although the physiological roles of such cells are currently unclear, analogous cells in the adult human kidney would be a valuable resource for the regeneration of kidneys in vitro.

Background Kidney structure There are more than a dozen distinct types of cell in the kidneys. The basic structural unit of the kidney is the nephron, which filters the blood to regulate the concentration of water and soluble substances such as sodium salts. Each nephron comprises several well-defined segments: the glomerulus, the proximal tubule, the loop of Henle, the distal tube and the collecting duct.

In embryo kidney organogenesis two primordial cell types are required to differentiate into all the different cell types in the kidney: metanephric mesenchymal cells and uteric bud cells. Kitamura, Sakurai and Makino produced kidney cells that could differentiate into a kidney-like structure without these primordial cell types, suggesting these are adult kidney stem cells.

Obtaining kidney stem cells The researchers microdissected adult rat kidneys into segments from the glomeruli, proximal convoluted tubule (S1/PCT), proximal straight tubule (S2, S3), medullary thick ascending limb of Henles loop and the collecting duct. They then grew the cells on mouse mesenchymal cells. While there is no known single biomarker for adult kidney stem cells, immunohistochemical anaylysis identified a number of markers in the kidney stem cells- that are found in embryonic or adult kidneys.

Follow this link:
Kidney organ regeneration research leaps forward

Read More...

Stem Cells to Revolutionise the Future of Diagnostic and Therapeutic Medicine

December 2nd, 2014 6:41 am

- As improved R&D climate supports development, stem cell therapeutics market expected to boom globally

KUALA LUMPUR, Malaysia, Dec. 2, 2014 /PRNewswire/ -- Stem cells have the potential to transform healthcare by enabling the cost-effective treatment of many conditions that currently have poor treatment options. This will be particularly important for the rapidly growing aged population as well as the rising proportion of patients with neurological and chronic conditions. Stem cells may enable regenerative treatments that avoid traditional drugs, devices and surgery for these patient groups.

New analysis from Frost & Sullivan, Analysis of the Global Stem Cell Market, finds that the market earned revenues of US$40.01 billion in 2013 and estimates this to nearly triple to US$117.66 billion in 2018 at a compound annual growth rate of 24.1 percent. The study covers human adult and embryonic stem cells. While North America is the market leader with more than half of the global stem cell market share, the Asia-Pacific is expected to record the highest compound annual growth rate (CAGR) during the forecast period. In fact, the APAC stem cell market, which was valued at US$5.60 billion in 2013, is projected to increase to US$18.71 billion by 2018.

For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/APAC_PR_DJeremiah_P805-52_10Nov14.

"The overall R&D funding for stem cell research has increased significantly in the past 5 to 10 years and will reach desired heights in the years to come," said Frost & Sullivan Healthcare Consultant Sanjeev Kumar. "The number of venture capital firms investing in stem cell research has risen and government funding agencies have begun to acknowledge the future benefits of the stem cell industry."

While the stiff regulations that previously guarded stem cell research have begun to relax, other legal and ethical issues continue to hamper research. For instance, research institutes that adopt policies addressing concerns surrounding the use of human embryonic tissues may hinder the overall research process, which usually involves several collaborative enterprises. Other market challenges include insurers' reluctance to pay for expensive stem cell therapies and the likelihood that patients themselves will be unable to afford these treatments.

"The global stem cell industry is in an early stage of development, with a handful of small and large participants," noted Kumar. "In the near future, mergers, acquisitions and collaborations will accelerate growth, with multinational companies and larger pharmaceutical companies playing a key role in facilitating these activities. As the market evolves, standards and new regulatory frameworks are expected to ease market challenges."

In the meantime, the market's growth potential is being underlined by promising results from clinical trials and the escalating importance of stem cell banking services across the globe. Eventually, the technology is expected to play a crucial function in various areas including neurological disorders, orthopaedics, cancer, haematological disorders, injuries and wound care, cardiovascular diseases, spinal cord injuries, diabetes, incontinence and liver disorders. Therapeutics manufacturers are also likely to explore the relevance of stem cells in other areas and combine them with existing applications to enhance treatment options.

Analysis of the Global Stem Cell Market is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. Frost & Sullivan's related studies include: Analysis of the Global Infectious Disease Diagnostics Market, Western European Companion Diagnostics Market, Analysis of the Global Biosimilars Market, and Analysis of the US Retinal Therapeutics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Here is the original post:
Stem Cells to Revolutionise the Future of Diagnostic and Therapeutic Medicine

Read More...

Global Stem Cells Group and Portal Medestetica to Launch Latin American Stem Cell Portal

December 2nd, 2014 6:41 am

MIAMI (PRWEB) December 01, 2014

GlobalStemCellsGroup.com has announced plans to team with Portal Medestetica, the largest physician portal in Lain America, to launch Portalstemcells.com, a new portal dedicated to providing physicians in Spain and Latin America with relevant information, clinical research news and products relating to stem cells and regenerative medicine.

The new collaboration between Global Stem Cells Group and Portal Medestetica will answer a growing need to expand the reach of high-impact news, studies and breakthroughs, and significantly advance the clinical utilization of stem cell research and clinical trials throughout Latin America. The Portalstemcells.com site is designed to help promote the latest state-of-the-art developments in regenerative medicine as they become available, and to share educational content with physicians throughout the region.

Portalstemcells.com will be the ideal vehicle to promote education and cutting-edge science throughout the region, says Ricardo de Cubas, founder of Global Stem Cells Group. The potential of regenerative medicine and stem cells therapies inspiring the medical community to find real opportunities to repair or replace tissue damaged from disease, relieve pain and provide the potential for curing chronic diseases where no cure existed before.

The Portalstemcells.com site is aimed at fostering growth and ethical development in the fast-moving field of stem cell medicine by filling a gap in the resources available throughout Latin America. The goal is to elevate the delivery of stem cell science in order to impact the lives of many patients worldwide.

For more information visit the Global Stem Cells website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Go here to see the original:
Global Stem Cells Group and Portal Medestetica to Launch Latin American Stem Cell Portal

Read More...

Stem Cell Therapy Skin Repair, Anti Aging and Anti Wrinkle Cream – As Seen On Tv – Look Younger – Video

December 2nd, 2014 6:40 am


Stem Cell Therapy Skin Repair, Anti Aging and Anti Wrinkle Cream - As Seen On Tv - Look Younger
http://www.ReadTheReviewsFirst.com Truvisage Anti-Aging Skin Care System Free Trial.

By: Greg Smith

See the original post here:
Stem Cell Therapy Skin Repair, Anti Aging and Anti Wrinkle Cream - As Seen On Tv - Look Younger - Video

Read More...

TESTIMONI LAMININE – Ginjal Diabetes dan Komplikasi – Video

December 1st, 2014 12:40 pm


TESTIMONI LAMININE - Ginjal Diabetes dan Komplikasi
Kunjungi website kami http://lamininestemcell.com Contacts: LIA MASTURA Phone: 081214804542 | WA: 088218497617 PIN BB: 7E97FF36 MIRA MASTURA Phone: 089657194720.

By: Laminine Nutrisi Stem Cell Terbaik

More:
TESTIMONI LAMININE - Ginjal Diabetes dan Komplikasi - Video

Read More...

Stem Cell Therapy Skin Repair and Anti-Wrinkle Cream – Video

November 30th, 2014 8:40 am


Stem Cell Therapy Skin Repair and Anti-Wrinkle Cream
http://www.ReadTheReviewsFirst.com Truvisage Anti-Aging Skin Care System Free Trial.

By: Greg Smith

Read more:
Stem Cell Therapy Skin Repair and Anti-Wrinkle Cream - Video

Read More...

Latest Hair Loss Research : Stem Cell Therapy and Stem Cell Nutrition for Hair Loss – Video

November 30th, 2014 8:40 am


Latest Hair Loss Research : Stem Cell Therapy and Stem Cell Nutrition for Hair Loss
For More Details Like Us : https://www.facebook.com/SuperStemCellNutrition.

By: Palu Sot

View post:
Latest Hair Loss Research : Stem Cell Therapy and Stem Cell Nutrition for Hair Loss - Video

Read More...

Q&A Jeunesse LUMINESCE with Dr Nathan Newman TQnvZgn J2w – Video

November 30th, 2014 4:42 am


Q A Jeunesse LUMINESCE with Dr Nathan Newman TQnvZgn J2w
Dr. Nathan Newman answers questions how adult stem cells are revolutionizing medicine and how they #39;re already being used in treatment of cosmetic and reconstructive to rejuvenate damaged tissues ...

By: Credo

Visit link:
Q&A Jeunesse LUMINESCE with Dr Nathan Newman TQnvZgn J2w - Video

Read More...

Page 1,206«..1020..1,2051,2061,2071,208..1,2201,230..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick